Loading...
•
Mar 31
Bio-Techne Q3 2025 Earnings Report
Bio-Techne reported increased revenue and adjusted EPS in Q3 2025, driven by strong performance in Protein Sciences and improved end-market conditions.
Key Takeaways
Bio-Techne delivered solid Q3 2025 results with 6% organic revenue growth and strong performance in its Protein Sciences segment. Adjusted EPS rose to $0.56, and the company achieved a 34.9% adjusted operating margin, supported by improved profitability and operational leverage.
Q3 2025 revenue reached $316,181,000, up 6% organically year-over-year.
Adjusted EPS increased to $0.56 from $0.48 a year ago.
Protein Sciences segment led growth with 7% organic increase and $227,687,000 in revenue.
GAAP net income dropped to $22,588,000 from $49,059,000, partly due to a one-time arbitration award.
Bio-Techne
Bio-Techne
Bio-Techne Revenue by Segment
Revenue by Segment
Protein Sciences Revenue
CapyFin.comDiagnostics & Spatial Bio Revenue
CapyFin.com Forward Guidance
Bio-Techne is optimistic about its future performance, citing strong geographic and end-market positioning, though macroeconomic conditions remain a potential challenge.
Positive Outlook
- Improved pharma end market conditions, particularly with large pharma partners.
- Strong performance in cell therapy and protein analysis instrumentation.
- Ongoing profitability initiatives supporting margins.
- Experienced leadership navigating current environment effectively.
- Robust product portfolio enabling scientific discovery and diagnostics.
Challenges Ahead
- GAAP operating margin declined due to one-time arbitration costs.
- Macroeconomic environment remains dynamic and uncertain.
- Foreign currency exchange had a negative impact on revenue.
- Diagnostics and Spatial Biology segment showed slower growth.
- Business held-for-sale adjustments reduced reported income.
Revenue & Expenses
Visualization of income flow from segment revenue to net income